A formal cost-benefit analysis wasn't done in SES-SMART, but the lower rates of restenosis and major adverse cardiovascular events
leave no doubt that drug-eluting stents, despite their higher acquistion cost, are cost-effective in small coronary arteries, Dr.
The primary endpoint of the VISTA-16 study is a composite of the time to occurrence of a secondary major adverse cardiovascular event
consisting of unstable angina requiring urgent hospitalization, myocardial infarction, stroke and cardiovascular death.
The primary safety objective is to evaluate the incidence of major adverse cardiovascular events
(MACE), defined as cardiovascular death, myocardial infarction or stroke.
BETonMACE will assess the effect of apabetalone (RVX-208) on time to first occurrence of Major Adverse Cardiovascular Events
(MACE) in high-risk type 2 DM patients with CAD.
Under the 2014 guidelines, it's also important to incorporate the surgical risk with an estimate of the individual's personalized risk of perioperative major adverse cardiovascular events
The rate of major adverse cardiovascular events
was higher among patients treated with varenicline than those on placebo in a meta-analysis, but the difference was not statistically significant, according to the latest Food and Drug Administration statement on the cardiovascular safety of the smoking cessation drug.
After 3 years, the patient is free from symptoms and has not presented major adverse cardiovascular events
Compared with noncarriers, the risk for developing major adverse cardiovascular events
The article is entitled South Asian Ethnicity as a Risk Factor for Major Adverse Cardiovascular Events
After Renal Transplantation.
Joint effects of N-terminal pro-B-type-natriuretic peptide and C-reactive protein vs angiographic severity in predicting major adverse cardiovascular events
and clinical restenosis after coronary angioplasty in patients with stable coronary artery disease.
Effect of muraglitazar on death and major adverse cardiovascular events
in patients with type 2 diabetes mellitus.
com) is a randomized, double-blind, placebo-controlled cardiovascular outcomes trial evaluating the occurrence of major adverse cardiovascular events
(MACE) in patients participating in the study.